Synergistic Antitumor Activity of Combination Therapy with a MET TKI Vabametkib and a Third-Generation EGFR TKI Lazertinib in MET-Amplified EGFR-Mutant NSCLC
Cancer Research and Treatment · 31.03.2026
DOI: 10.4143/crt.2025.1399 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Research and Treatment, online erschienen am 31.03.2026. Verfasst von Dong Kwon Kim und 9 weiteren Autor:innen. Beteiligte Einrichtung: Yonsei Biomedical Research Institute, Yonsei University College of Medicine, Seoul, Korea. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
Purpose
Third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKIs) improved outcomes in EGFR-mutant non-small cell lung cancer (NSCLC); however, the subsequent development of resistance emphasizes the necessity of overcoming this therapeutic limitation. MET amplification is one of the major resistance mechanism in EGFR-mutant NSCLC, bypassing EGFR inhibition by activating cell survival, proliferation, and metastasis. Combining MET- and EGFR-TKIs is thus emerging as a promising therapeutic strategy to overcome resistance to EGFR TKIs. Materials and Methods: This study aimed to investigate the combination of the selective MET TKI vabametkib and a third-generation EGFR TKI lazertinib in MET-amplified EGFR TKI resistance models. Inhibition of downstream signaling and cell proliferation by vabametkib plus lazertinib were evaluated in osimertinib-resistance NSCLC cell lines (HCC827-AR) and patient-derived organoid (YUO-010) by western blot and Cell Titer-Glo assay.
Results
In vitro studies demonstrated that vabametkib plus lazertinib synergistically inhibited EGFR/MET phosphorylation, leading to markedly enhanced anti-proliferative effects through downstream PI3K/AKT and MAPK pathway blockade. To investigate the antitumor effects in in vivo, we employed two patient-derived xenograft (PDX) models (YHIM-1035(1) and YHIM-1053) harboring MET amplification, as characterized by whole-exome sequencing or droplet digital PCR (ddPCR). Consistent with the in vitro findings, treatment with vabametkib plus lazertinib produced pronounced suppression of tumor growth in both models through a synergistic mechanism.
Conclusion
These findings establish vabametkib plus lazertinib as a promising strategy for MET-amplified NSCLC, currently under evaluation in an ongoing phase II clinical trial (NCT05541822).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Yonsei Biomedical Research Institute, Yonsei University College of Medicine, Seoul, Korea.
- Department of Biology, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, USA.
- Department of Hematology-Oncology, Inje University Haeundae Paik Hospital, Busan, Korea.
- R&D Center, ABION Inc., Seoul, Korea.
- Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
- Yonsei New Il Han Institute for Integrative Lung Cancer Research, Yonsei University College of Medicine, Seoul, Korea.
Zitieren
APA
Kim, D. K., Park, J. W., Cho, H. B., Choi, S. J., Lee, S. S., Kim, Y., Lee, J. B., Lim, S. M., Yu, M. R., & Cho, B. C. (2026). Synergistic Antitumor Activity of Combination Therapy with a MET TKI Vabametkib and a Third-Generation EGFR TKI Lazertinib in MET-Amplified EGFR-Mutant NSCLC. Cancer Research and Treatment. https://doi.org/10.4143/crt.2025.1399
Vancouver
Kim DK, Park JW, Cho HB, Choi SJ, Lee SS, Kim Y, et al. Synergistic Antitumor Activity of Combination Therapy with a MET TKI Vabametkib and a Third-Generation EGFR TKI Lazertinib in MET-Amplified EGFR-Mutant NSCLC. Cancer Research and Treatment. 2026. doi:10.4143/crt.2025.1399
BibTeX
@article{Kim2026,
author = {Kim, Dong Kwon and Park, Jin Woo and Cho, Hyeon Bin and Choi, Su Jin and Lee, Sung Sook and Kim, YeongMun and Lee, Jii Bum and Lim, Sun Min and Yu, Mi Ra and Cho, Byoung Chul},
title = {Synergistic Antitumor Activity of Combination Therapy with a MET TKI Vabametkib and a Third-Generation EGFR TKI Lazertinib in MET-Amplified EGFR-Mutant NSCLC},
journal = {Cancer Research and Treatment},
year = {2026},
doi = {10.4143/crt.2025.1399}
}
EUVIMED